Search

CN-120796134-B - Application of bacteroides in reducing blood sugar

CN120796134BCN 120796134 BCN120796134 BCN 120796134BCN-120796134-B

Abstract

The invention relates to an application of bacteroides in reducing blood sugar. Specifically, the invention provides a common bacteroides (Bacteroides plebeius) J2525 with the function of reducing blood sugar, which is a gram-negative bacterium separated and purified from human excrement, and the gram-negative bacterium is preserved in China general microbiological culture Collection center (CHINA GENERAL Microbiological Culture Collection Center, CGMCC) with the preservation number of CGMCC No.46398 in the period of 25 of 2025. The invention also provides application of the bacteroides thetaiotaomicron J2525 in preparing a product for reducing blood sugar, improving glucose tolerance or improving insulin sensitivity. The invention shows that the Bacteroides thetaiotaomicron strain J2525 can be developed as a probiotic with good blood sugar reducing effect, and has higher reference value for clinical application of the strain.

Inventors

  • JIANG ZENGLIANG
  • LIANG YUHUI
  • CHEN SHIGUO
  • YE XINGQIAN
  • LIU DONGHONG
  • Tuo Yiran
  • ZHAO DAIQI
  • MAO YANGCHEN

Assignees

  • 浙江大学

Dates

Publication Date
20260505
Application Date
20250723

Claims (3)

  1. 1. A medicine for reducing blood sugar is characterized by comprising live bacteria of bacteroides (Bacteroides plebeius) J2525, fermentation liquor or fermentation liquor extract thereof, wherein the bacteroides J2525 is preserved in China general microbiological culture collection center (CHINA GENERAL Microbiological Culture Collection Center, CGMCC) in the 4 th month 25 of 2025, and the preservation number is CGMCC NO. 46398.
  2. 2. The application of the common bacteroides J2525 in preparing the hypoglycemic medicine is characterized in that the common bacteroides J2525 is preserved in China general microbiological culture collection center (CHINA GENERAL Microbiological Culture Collection Center, CGMCC) in the 4 th month 25 of 2025, and the preservation number is CGMCC NO. 46398.
  3. 3. The use according to claim 2, wherein the pharmaceutical product comprises live bacteroides vulgare J2525, a fermentation broth or a fermentation broth extract thereof.

Description

Application of bacteroides in reducing blood sugar Technical Field The invention relates to the field of microorganisms, in particular to application of bacteroides oleiciplenus in reducing blood sugar. Background Hyperglycemia is the most important clinical manifestation and diagnosis basis of diabetes mellitus, and is also the core pathological link of occurrence and development of various chronic metabolic diseases. Long-term or chronic hyperglycemic conditions can cause irreversible damage to body vessels, nerves, and multiple vital organs, with serious health consequences. Various metabolic disorders caused by hyperglycemia have become a global significant public health challenge. The prior art shows that intestinal flora is used as a 'metabolic organ' and an 'immunomodulator' which are indispensable to a host, and plays a key mediating role in the pathophysiological process of diabetes by regulating energy metabolism, maintaining the integrity of intestinal barriers, producing key metabolites such as short-chain fatty acids and the like and affecting systemic inflammation level. Thus, targeted modulation of intestinal flora to ameliorate host glucose metabolism disorders has become a well-established promising intervention strategy in the art. Currently, traditional therapeutic approaches include oral hypoglycemic drugs and insulin preparations, which, although capable of controlling blood glucose to some extent, often have adverse effects in clinical use, including low blood glucose risk, gastrointestinal discomfort, weight gain, and increased burden of liver and kidney metabolism. These drawbacks seriously affect the safety of its long-term use and patient compliance. Therefore, there is an urgent need in the industry to develop new intervention techniques with clear sources, clear mechanisms of action and higher safety. Screening and identifying specific functional strains capable of effectively regulating glycolipid metabolic disorders from human intestinal symbiotic bacteria has become a technical hotspot for developing new-generation diabetes biological therapies. At present, no systematic research report or related technical application for preventing, relieving or treating hyperglycemia by using the common bacteroides (Bacteroides plebeius) is disclosed. Disclosure of Invention The invention provides a common bacteroides (Bacteroides plebeius) J2525 with a blood sugar reducing function, which is a gram-negative bacterium separated and purified from human excrement, is an anaerobic bacterium species living in human intestinal tracts, and is preserved in China general microbiological culture collection center (CHINA GENERAL Microbiological Culture Collection Center, CGMCC) at the 25 th month of 2025, and the preservation number is CGMCC NO. 46398. According to the invention, animal intervention experiments prove that the blood sugar improvement effect of the bacteroides farinae on metabolic disorder model mice is improved. The mice were monitored for body weight and blood glucose by long-term intervention experiments with usual bacteroides in the mice, and were tested for glucose tolerance and insulin tolerance 6 weeks after the intervention. The results prove that the bacteroides thetaiotaomicron J2525 of the present invention does not affect the weight and the feeding amount of the mice, but can significantly improve the fasting blood glucose and glucose tolerance and insulin resistance states of the high-fat diet fed mice. In this case, the present invention includes, but is not limited to, the following: In one aspect, the invention provides a general bacillus J2525 with a blood sugar reducing function, which is preserved in China general microbiological culture collection center (CHINA GENERAL Microbiological Culture Collection Center, CGMCC) for 4-25 days in 2025, and the preservation number is CGMCC NO. 46398. In another aspect, the invention provides a hypoglycemic drug, which comprises the live bacteria of bacteroides vulgare J2525, fermentation broth or fermentation broth extract thereof. In another aspect, the invention provides a medicine for improving glucose tolerance, which comprises the live bacteroides thetaiotaomicron J2525, a fermentation broth or a fermentation broth extract thereof. In another aspect, the invention provides a medicine for improving insulin sensitivity, which comprises the live bacteria of bacteroides thetaiotaomicron J2525, a fermentation broth or a fermentation broth extract thereof. In a further aspect, the invention provides the application of the bacteroides thetaiotaomicron J2525 in preparing a hypoglycemic medicine. In a further aspect, the invention provides the use of the bacteroides thetaiotaomicron J2525 as described herein in the preparation of a medicament for increasing glucose tolerance. In a further aspect, the invention provides the use of the bacteroides thetaiotaomicron J2525 as described herein in the manufacture of a medicament for increa